Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, U.S.A.
Department of Otorhinolaryngology, University of Lübeck, Lübeck, Germany.
Laryngoscope. 2021 Nov;131(11):2616-2624. doi: 10.1002/lary.29755. Epub 2021 Jul 19.
OBJECTIVES/HYPOTHESIS: To provide the ADHERE registry Upper Airway Stimulation (UAS) outcomes update, including analyses grouped by body mass index (BMI) and therapy discomfort.
Prospective observational study.
ADHERE captures UAS outcomes including apnea-hypopnea index (AHI), Epworth sleepiness scale (ESS), therapy usage, patient satisfaction, clinician assessment, and safety over a 1-year period. BMI ≤32 kg/m (BMI ) and 32 < BMI ≤35 kg/m (BMI ) group outcomes were examined.
One thousand eight hundred forty-nine patients enrolled in ADHERE, 1,019 reached final visit, 843 completed the visit. Significant changes in AHI (-20.9, P < .0001) and ESS (- 4.4, P < .0001) were demonstrated. Mean therapy usage was 5.6 ± 2.2 hr/day. Significant therapy use difference was present in patients with reported discomfort versus no discomfort (4.9 ± 2.5 vs. 5.7 ± 2.1 hr/day, P = .01). Patients with discomfort had higher final visit mean AHI versus without discomfort (18.9 ± 18.5 vs. 13.5 ± 13.7 events/hr, P = .01). Changes in AHI and ESS were not significantly different. Serious adverse events reported in 2.3% of patients. Device revision rate was 1.9%. Surgical success was less likely in BMI versus BMI patients (59.8% vs. 72.2%, P = .02). There was a significant therapy use difference: 5.8 ± 2.0 hr/day in BMI versus 5.2 ± 2.2 hr/day in BMI (P = .028).
Data from ADHERE demonstrate high efficacy rates for UAS. Although surgical response rate differs between BMI and BMI patient groups, the AHI and ESS reduction is similar. Discomfort affects therapy adherence and efficacy. Thus, proper therapy settings adjustment to ensure comfort is imperative to improve outcomes.
4 Laryngoscope, 131:2616-2624, 2021.
目的/假设:提供 ADHERE 登记处的上气道刺激 (UAS) 结果更新,包括按体重指数 (BMI) 和治疗不适分组的分析。
前瞻性观察研究。
ADHERE 记录 UAS 结果,包括呼吸暂停低通气指数 (AHI)、嗜睡量表 (ESS)、治疗使用情况、患者满意度、临床医生评估和 1 年内的安全性。检查 BMI ≤32kg/m2 (BMI ) 和 32 < BMI ≤35kg/m2 (BMI ) 组的结果。
1849 名患者参加了 ADHERE,1019 名患者达到了最终就诊,843 名患者完成了就诊。AHI(-20.9,P <.0001)和 ESS(-4.4,P <.0001)显著降低。平均治疗使用率为 5.6±2.2 小时/天。有不适报告的患者与无不适报告的患者之间的治疗使用差异显著(4.9±2.5 与 5.7±2.1 小时/天,P=0.01)。有不适的患者最后一次就诊的平均 AHI 高于无不适的患者(18.9±18.5 与 13.5±13.7 事件/小时,P=0.01)。AHI 和 ESS 的变化无显著差异。2.3%的患者报告了严重不良事件。设备修订率为 1.9%。与 BMI 患者相比,BMI 患者的手术成功率较低(59.8%比 72.2%,P=0.02)。治疗使用差异显著:BMI 患者为 5.8±2.0 小时/天,BMI 患者为 5.2±2.2 小时/天(P=0.028)。
ADHERE 的数据表明 UAS 的疗效很高。尽管 BMI 和 BMI 患者组之间的手术反应率不同,但 AHI 和 ESS 的降低是相似的。不适会影响治疗的依从性和疗效。因此,适当调整治疗设置以确保舒适度对于改善结果至关重要。
4 级喉镜,131:2616-2624,2021 年。